Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 122
Filter
1.
Oncogene ; 31(35): 3939-48, 2012 Aug 30.
Article in English | MEDLINE | ID: mdl-22139082

ABSTRACT

A clearer definition of the molecular determinants that drive the development and progression of prostate cancer (PCa) is urgently needed. Efforts to map recurrent somatic deletions in the tumor genome, especially homozygous deletions (HODs), have provided important positional information in the search for cancer-causing genes. Analyzing HODs in the tumors of 244 patients from two independent cohorts and 22 PCa xenografts using high-resolution single-nucleotide polymorphism arrays, herein we report the identification of CHD1, a chromatin remodeler, as one of the most frequently homozygously deleted genes in PCa, second only to PTEN in this regard. The HODs observed in CHD1, including deletions affecting only internal exons of CHD1, were found to completely extinguish the expression of mRNA of this gene in PCa xenografts. Loss of this chromatin remodeler in clinical specimens is significantly associated with an increased number of additional chromosomal deletions, both hemi- and homozygous, especially on 2q, 5q and 6q. Together with the deletions observed in HEK293 cells stably transfected with CHD1 small hairpin RNA, these data suggest a causal relationship. Downregulation of Chd1 in mouse prostate epithelial cells caused dramatic morphological changes indicative of increased invasiveness, but did not result in transformation. Indicating a new role of CHD1, these findings collectively suggest that distinct CHD1-associated alterations of genomic structure evolve during and are required for the development of PCa.


Subject(s)
Chromatin Assembly and Disassembly , DNA Helicases/genetics , DNA Helicases/physiology , DNA-Binding Proteins/genetics , DNA-Binding Proteins/physiology , Gene Deletion , Prostatic Neoplasms/genetics , Animals , Cell Line , Down-Regulation , HEK293 Cells , Homozygote , Humans , Male , Mice , Neoplasm Transplantation , Oligonucleotide Array Sequence Analysis , PTEN Phosphohydrolase/genetics , Polymorphism, Single Nucleotide , RNA Interference , RNA, Messenger/genetics , RNA, Messenger/metabolism , RNA, Small Interfering/genetics , Transplantation, Heterologous
2.
Clin Exp Dermatol ; 32(2): 145-7, 2007 Mar.
Article in English | MEDLINE | ID: mdl-17342794

ABSTRACT

There is little information on the relative efficacy of topical tacrolimus and corticosteroids in the treatment of atopic dermatitis (AD) in children. In a single-centre, prospective, observer-blinded, side-to-side comparative study (ISRCTN65507338), 96 children with moderately severe AD were enrolled. The study aimed to compare the relative effectiveness of the child's usual topical corticosteroid with 0.03% tacrolimus ointment applied for 1 week, and if there was no difference, 0.1% tacrolimus ointment applied for a further week. Topical tacrolimus was found to be more effective than topical corticosteroid in 72 of the 93 children (77%) who completed the study. Using multiple-regression analysis with age, gender, pretreatment surface area affected and pretreatment corticosteroid potency as covariants, the only factor that reduced the chance of observing a beneficial effect with tacrolimus was moderate or potent topical corticosteroid use (OR = 0.13; 95% CI 0.02-0.74).


Subject(s)
Adrenal Cortex Hormones/therapeutic use , Dermatitis, Atopic/drug therapy , Immunosuppressive Agents/therapeutic use , Tacrolimus/therapeutic use , Administration, Topical , Adolescent , Child , Child, Preschool , Female , Humans , Infant , Male , Prospective Studies
3.
Diagn Cytopathol ; 31(5): 352-7, 2004 Nov.
Article in English | MEDLINE | ID: mdl-15468118

ABSTRACT

Although primary carcinomas account for the majority of breast malignancies, nonepithelial malignancies form a subset that must be differentiated accurately for treatment purposes. The purpose of this study was to identify cytological characteristics that differentiate between these two entities. Twenty-six fine-needle aspiration (FNA) specimens with histological correlation were reviewed (five lymphomas, two myelomas, six sarcomas, seven melanomas, and six carcinomas). On review, nonepithelial tumors presented as single cells with scant or ill-defined cytoplasm with rare cluster formations present. In contrast, carcinomas were arranged predominantly in clusters and contained more-defined, abundant, and sometimes vacuolated cytoplasm. Moreover, a major aid to diagnosis was an accurate clinical history. We conclude that nonepithelial malignancies of the breast are best differentiated from epithelial malignancies by a combination of cytological features and clinical information. These findings emphasize the importance of the triple test, in which integration of cytological findings and clinical information play a key role.


Subject(s)
Breast Neoplasms, Male/pathology , Carcinoma/pathology , Melanoma/pathology , Multiple Myeloma/pathology , Sarcoma/pathology , Adult , Aged , Aged, 80 and over , Biomarkers, Tumor/analysis , Breast Neoplasms, Male/chemistry , Carcinoma/chemistry , Diagnosis, Differential , Female , Humans , Male , Melanoma/chemistry , Middle Aged , Multiple Myeloma/chemistry , Sarcoma/chemistry
4.
Arch Pathol Lab Med ; 128(5): 565-7, 2004 May.
Article in English | MEDLINE | ID: mdl-15086301

ABSTRACT

Melanosis coli is a well-known condition in which macrophages filled with a lipofuscin-like pigment are found in the colonic lamina propria. The condition has been associated with the ingestion of anthracene laxatives and is believed to be caused by increased epithelial apoptosis. Although melanosis coli is a frequent finding in colonic biopsies and resection specimens, to our knowledge the presence of identical pigment in macrophages of pericolonic lymph nodes has been reported in only 4 other patients in the English literature. We report the case of a patient who underwent a left hemicolectomy for colonic adenocarcinoma and was found incidentally to have melanosis coli associated with long-term use of the herbal laxative Swiss Kriss, not only in his colonic mucosa, but also in the colonic submucosa and in his pericolonic lymph nodes.


Subject(s)
Adenocarcinoma/complications , Cathartics/adverse effects , Colon , Colonic Neoplasms/complications , Lymph Nodes/pathology , Melanosis/pathology , Aged , Humans , Male , Melanosis/chemically induced , Melanosis/complications , Plants, Medicinal
5.
Diagn Cytopathol ; 30(1): 19-23, 2004 Jan.
Article in English | MEDLINE | ID: mdl-14696140

ABSTRACT

Synovial sarcoma (SS) is a high-grade sarcoma that can be diagnosed in cytology with certainty only when it presents with a biphasic pattern. Monophasic SS (MSS), however, is a diagnostic consideration when a uniform spindle cell population is present. The purpose of this study was to evaluate a series of cytologic cases of MSS and its cytologic presentation. Twenty-one FNAs of histologically confirmed MSS were reviewed. Specimens consisted of tissue fragments and single cells containing scant granular cytoplasm, medium-sized nuclei, and coarse chromatin. A monotonous spindle pattern with comma-shaped nuclei was present in 5 cases. Sixteen cases contained oval and spindled nuclei. Eight of these specimens contained round nuclei, and 5 of these cases showed prominent nucleoli and cohesive clusters, reminiscent of biphasic SS. We conclude that a spectrum of cytologic findings can be seen in MSS, including a secondary population of cells with morphology usually typical of biphasic SS.


Subject(s)
Sarcoma, Synovial/pathology , Soft Tissue Neoplasms/pathology , Adult , Aged , Biopsy, Fine-Needle , Diagnosis, Differential , Female , Humans , Immunohistochemistry , Male , Microscopy, Electron , Middle Aged , Retrospective Studies , Reverse Transcriptase Polymerase Chain Reaction , Sarcoma, Synovial/genetics , Sarcoma, Synovial/ultrastructure , Soft Tissue Neoplasms/genetics , Soft Tissue Neoplasms/ultrastructure , Translocation, Genetic
6.
Ann Surg Oncol ; 9(3): 235-42, 2002 Apr.
Article in English | MEDLINE | ID: mdl-11923129

ABSTRACT

BACKGROUND: After neoadjuvant chemotherapy, women with locally advanced breast cancer (LABC) undergo a modified radical mastectomy or lumpectomy with axillary lymph node dissection (ALND) and radiotherapy. Sentinel lymphadenectomy (SL) is accepted for axillary evaluation in early breast cancer. We assessed the feasibility and predictive value of SL after neoadjuvant chemotherapy. METHODS: Eligible women received neoadjuvant therapy for LABC and were scheduled to undergo a definitive surgical procedure. Vital blue dye SL was attempted followed by level I and II axillary dissection. RESULTS: SL was successful in 29 of 34 patients (detection rate, 85%). Thirteen patients (45%) had positive nodes, and eight (28%) had negative nodes on both SL and ALND. In five patients (17%), the sentinel node was the only positive node identified. Overall, there was a 90% concordance between SL and ALND. The false-negative rate and negative predictive value were 14% and 73%, respectively. Among the subgroup without inflammatory cancer, the detection and concordance rates were 89% and 96%, respectively. The false-negative rate was 6%, and the negative predictive value was 88%. CONCLUSIONS: SL after neoadjuvant chemotherapy may reliably predict axillary staging except in inflammatory breast cancer. Further studies are required to assess the utility of SL as the only mode of axillary evaluation in these women.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Breast Neoplasms/drug therapy , Breast Neoplasms/pathology , Sentinel Lymph Node Biopsy , Adult , Aged , Axilla , Breast Neoplasms/surgery , False Negative Reactions , Female , Humans , Lymphatic Metastasis/pathology , Middle Aged , Neoadjuvant Therapy , Predictive Value of Tests , Sentinel Lymph Node Biopsy/methods
7.
Nat Genet ; 30(2): 181-4, 2002 Feb.
Article in English | MEDLINE | ID: mdl-11799394

ABSTRACT

Although prostate cancer is the most common non-cutaneous malignancy diagnosed in men in the United States, little is known about inherited factors that influence its genetic predisposition. Here we report that germline mutations in the gene encoding 2'-5'-oligoadenylate(2-5A)-dependent RNase L (RNASEL) segregate in prostate cancer families that show linkage to the HPC1 (hereditary prostate cancer 1) region at 1q24-25 (ref. 9). We identified RNASEL by a positional cloning/candidate gene method, and show that a nonsense mutation and a mutation in an initiation codon of RNASEL segregate independently in two HPC1-linked families. Inactive RNASEL alleles are present at a low frequency in the general population. RNASEL regulates cell proliferation and apoptosis through the interferon-regulated 2-5A pathway and has been suggested to be a candidate tumor suppressor gene. We found that microdissected tumors with a germline mutation showed loss of heterozygosity and loss of RNase L protein, and that RNASEL activity was reduced in lymphoblasts from heterozyogous individuals compared with family members who were homozygous with respect to the wildtype allele. Thus, germline mutations in RNASEL may be of diagnostic value, and the 2-5A pathway might provide opportunities for developing therapies for those with prostate cancer.


Subject(s)
Endoribonucleases/genetics , Germ-Line Mutation , Oncogenes , Prostatic Neoplasms/enzymology , Prostatic Neoplasms/genetics , Adenine Nucleotides/metabolism , Base Sequence , Case-Control Studies , DNA Mutational Analysis , DNA, Neoplasm/genetics , Female , Genetic Linkage , Heterozygote , Homozygote , Humans , Loss of Heterozygosity , Lymphocytes/enzymology , Male , Oligoribonucleotides/metabolism , Pedigree
8.
Cancer Res ; 61(24): 8617-23, 2001 Dec 15.
Article in English | MEDLINE | ID: mdl-11751373

ABSTRACT

Cyclooxygenase-2 (COX-2) is the inducible isoform of the rate-limiting enzymes that convert arachidonic acid to proinflammatory prostaglandins as well as a primary target for nonsteroidal anti-inflammatory drugs. Accumulating evidence suggests that up-regulation of COX-2 is associated with carcinogenesis in multiple organ systems including the large bowel, lung, breast, and prostate. In this report, we examine the expression of COX-2 protein and mRNA in prostate tissue containing various lesions and in prostate cancer cell lines. In the cell lines, LNCaP, DU145, PC-3, and TSU, COX-2 protein expression was undetectable under basal conditions but could be induced transiently by phorbol ester treatment in PC-3 and TSU cells, but not in DU145 and LNCaP cells. Immunohistochemical analysis of 144 human prostate cancer cases suggested that, in contrast to several previous reports, there was no consistent overexpression of COX-2 in established prostate cancer or high-grade prostatic intraepithelial neoplasia, as compared with adjacent normal prostate tissue. Positive staining was seen only in scattered cells (<1%) in both tumor and normal tissue regions but was much more consistently observed in areas of proliferative inflammatory atrophy, lesions that have been implicated in prostatic carcinogenesis. Staining was also seen at times in macrophages. Western blotting and quantitative RT-PCR analyses confirmed these patterns of expression. These results suggest that if nonsteroidal anti-inflammatory drugs are indeed chemopreventive and/or chemotherapeutic for prostate cancer, their effects are likely to be mediated by modulating COX-2 activity in non-PCa cells (either inflammatory cells or atrophic epithelial cells) or by affecting a COX-2-independent pathway.


Subject(s)
Isoenzymes/biosynthesis , Prostaglandin-Endoperoxide Synthases/biosynthesis , Prostate/pathology , Prostatic Neoplasms/enzymology , Atrophy/enzymology , Blotting, Western , Cyclooxygenase 2 , Disease Progression , Epithelium/enzymology , Epithelium/pathology , Humans , Immunohistochemistry , Isoenzymes/genetics , Male , Membrane Proteins , Prostaglandin-Endoperoxide Synthases/genetics , Prostatic Neoplasms/genetics , Prostatic Neoplasms/pathology , RNA, Messenger/biosynthesis , RNA, Messenger/genetics , Reverse Transcriptase Polymerase Chain Reaction , Stromal Cells/enzymology , Stromal Cells/pathology , Tumor Cells, Cultured , Up-Regulation
9.
Cell Motil Cytoskeleton ; 50(2): 101-13, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11746675

ABSTRACT

Recently, the large filamentous striated-muscle protein titin has been observed in non-muscle cells, and, in one instance, has been proposed to have a nuclear function as a chromosomal component contributing to structure and elasticity. In this study, we sought to further characterize the presumptive nuclear isoform of titin. Immunofluorescence microscopy with multiple titin-specific monoclonal antibodies shows localization to the nucleus in interphase cells and to the spindle machinery in mitotic cells in all cell types examined; localization to condensed chromosomes is not observed. An abundant 700-kDa phosphoprotein is the predominant species immunoprecipitated with these antibodies. Sequencing of peptide fragments of the immunopurified protein reveals identity to AHNAK, a nuclear phosphoprotein, an identification that was confirmed by Western blot analysis with antibodies to AHNAK and peptide fragmentation patterns. Sequence comparison suggests similarities between the repetitive heptad phi+/-phiP+/-phi+/- motif in AHNAK and the PEVK region of titin, potentially explaining the cross-reactivity observed between AHNAK antibodies and titin antibodies. Interestingly, although some AHNAK antibodies stain interphase nuclei, no evidence of mitotic spindle localization is seen, suggesting that the identity of the protein at the latter location is more closely related to titin than AHNAK. This concept is further supported by observations that cell lines not expressing AHNAK have similar antititin antibody localization to the mitotic spindle. We conclude that (1) multiple titin antibodies, particularly those recognizing the PEVK region, cross-react with AHNAK, and (2) the mitotic spindle staining observed with antititin antibodies is most likely due to the association of titin or a titin-like molecule with this structure.


Subject(s)
Cell Nucleus/metabolism , Membrane Proteins/metabolism , Mitosis/physiology , Muscle Proteins/metabolism , Neoplasm Proteins/metabolism , Protein Kinases/metabolism , Spindle Apparatus/metabolism , Amino Acid Motifs/immunology , Amino Acid Sequence , Antibodies/immunology , Antibody Specificity/immunology , Cell Nucleus/ultrastructure , Connectin , Cross Reactions/immunology , Humans , Membrane Proteins/genetics , Membrane Proteins/immunology , Molecular Sequence Data , Molecular Weight , Muscle Proteins/genetics , Muscle Proteins/immunology , Neoplasm Proteins/genetics , Neoplasm Proteins/immunology , Protein Kinases/genetics , Protein Kinases/immunology , Sequence Homology, Amino Acid , Spindle Apparatus/immunology , Spindle Apparatus/ultrastructure
10.
J Exp Med ; 194(7): 873-82, 2001 Oct 01.
Article in English | MEDLINE | ID: mdl-11581310

ABSTRACT

Experimental autoimmune encephalomyelitis (EAE), a model for multiple sclerosis, can be induced by immunization with a number of myelin antigens. In particular, myelin oligodendrocyte glycoprotein, a central nervous system (CNS)-specific antigen expressed on the myelin surface, is able to induce a paralytic MS-like disease with extensive CNS inflammation and demyelination in several strains of animals. Although not well understood, the egress of immune cells into the CNS in EAE is governed by a complex interplay between pro and antiinflammatory cytokines and chemokines. The hematopoietic growth factor, granulocyte macrophage colony-stimulating factor (GM-CSF), is considered to play a central role in maintaining chronic inflammation. The present study was designed to investigate the previously unexplored role of GM-CSF in autoimmune-mediated demyelination. GM-CSF(-/)- mice are resistant to EAE, display decreased antigen-specific proliferation of splenocytes, and fail to sustain immune cell infiltrates in the CNS, thus revealing key activities for GM-CSF in the development of inflammatory demyelinating lesions and control of migration and/or proliferation of leukocytes within the CNS. These results hold implications for the pathogenesis of inflammatory and demyelinating diseases and may provide the basis for more effective therapies for inflammatory diseases, and more specifically for multiple sclerosis.


Subject(s)
Encephalomyelitis, Autoimmune, Experimental/therapy , Granulocyte-Macrophage Colony-Stimulating Factor/immunology , Multiple Sclerosis/therapy , Animals , Autoantibodies/blood , Disease Models, Animal , Encephalomyelitis, Autoimmune, Experimental/etiology , Granulocyte-Macrophage Colony-Stimulating Factor/deficiency , Immunity, Innate , Immunotherapy , Mice , Mice, Inbred NOD , Mice, Mutant Strains , Multiple Sclerosis/etiology , Myelin Proteins , Myelin-Associated Glycoprotein/immunology , Myelin-Oligodendrocyte Glycoprotein , T-Lymphocytes/immunology
11.
Transplantation ; 72(3): 477-9, 2001 Aug 15.
Article in English | MEDLINE | ID: mdl-11502978

ABSTRACT

BACKGROUND: We describe a rare case of necrotizing fasciitis involving Candida albicans, an organism that has been reported to have a minimal potential for invasive soft tissue infection. In this case, immunosuppression, chronic renal failure, and a history of diabetes mellitus were predisposing factors. METHODS: The medical record and histopathologic material were examined. The clinical literature was reviewed for previous cases of C albicans necrotizing fasciitis. RESULTS: A review of the literature showed that in solid organ transplant recipients, localized fungal soft tissue infection is infrequent, with only 35 cases reported between 1974 and 1992. Necrotizing fasciitis caused by C albicans is extremely rare in the modern era of solid organ transplantation. CONCLUSIONS: The management of transplant patients at risk for invasive fungal infection warrants a high index of suspicion for fungal necrotizing fasciitis in the setting of wound infection and merits a thorough investigation for atypical pathogens.


Subject(s)
Candidiasis , Fasciitis/microbiology , Kidney Transplantation , Postoperative Complications , Candidiasis/etiology , Diabetic Nephropathies/complications , Humans , Immunosuppression Therapy/adverse effects , Kidney Failure, Chronic/complications , Kidney Failure, Chronic/surgery , Male , Middle Aged
12.
Cancer Res ; 61(16): 5969-73, 2001 Aug 15.
Article in English | MEDLINE | ID: mdl-11507036

ABSTRACT

Research into molecular and genetic mechanisms underlying familial prostate cancer would be greatly advanced by in vitro models of prostate tumor cells representing primary tumors. We have successfully established an immortalized human prostate epithelial cell culture derived from primary tumors of familial prostate cancer patients with telomerase. The actively proliferating early-passaged 957E cells were transduced through infection with a retrovirus expressing the human telomerase catalytic subunit, human telomerase reverse transcriptase (hTERT). A high level of telomerase activity was detected in 957E/hTERT cells, but not in 957E cells. 957E/hTERT cells are currently growing well at passage 40, whereas 957E cells senesced at passage 5. 957E/hTERT cells exhibit epithelial morphology. Expression of an androgen-regulated prostate specific homeobox gene NKX3.1 and an epithelial cell-specific cytokeratin 8, but not prostate specific antigen or androgen receptor, was detected in 957E/hTERT cells. Prostatic stem cell antigen and p16 were also expressed in this line. 957E/hTERT cells showed growth inhibition when exposed to retinoic acid and transforming growth factor beta1, potent inhibitors of prostate epithelial cell growth. Chromosome analysis showed that the 957E/hTERT cell line (passage 10) was near diploid human male (XY), with most chromosome counts in the 44-46 range. However, there was random loss of chromosomes 8, 13, X, Y, and alteration in chromosome 4q. The late passage 957E/hTERT cell line (passage 32) was karyologically similar to the early passage 957E/hTERT cell line (passage 10) and also had the same alteration of 4q observed in the early passage 957E/hTERT cell line (passage 10) as well as a trisomy of chromosome 20. The well-characterized human cancer lines derived from such patients will be useful for the identification and characterization of prostate cancer susceptibility genes. This is the first documented case of an established human prostate cancer cell line from primary tumor of a familial prostate cancer patient.


Subject(s)
Adenocarcinoma/genetics , Prostatic Neoplasms/genetics , Tumor Cells, Cultured , Adenocarcinoma/enzymology , Adenocarcinoma/pathology , Adult , Cell Division/drug effects , DNA-Binding Proteins , Growth Inhibitors/pharmacology , Humans , In Situ Hybridization, Fluorescence , Karyotyping , Male , Prostatic Neoplasms/enzymology , Prostatic Neoplasms/pathology , Retroviridae/genetics , Reverse Transcriptase Polymerase Chain Reaction , Telomerase/genetics , Telomerase/metabolism , Transduction, Genetic , Transforming Growth Factor beta/pharmacology , Transforming Growth Factor beta1 , Tretinoin/pharmacology
13.
Am J Hum Genet ; 69(2): 341-50, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11443539

ABSTRACT

Multiple lines of evidence have implicated the short arm of chromosome 8 as harboring genes important in prostate carcinogenesis. Although most of this evidence comes from the identification of frequent somatic alterations of 8p loci in prostate cancer cells (e.g., loss of heterozygosity), studies have also suggested a role for 8p genes in mediation of inherited susceptibility to prostate cancer. To further examine this latter possibility, we performed linkage analyses, in 159 pedigrees affected by hereditary prostate cancer (HPC), using 24 markers on the short arm of chromosome 8. In the complete set of families, evidence for prostate cancer linkage was found at 8p22-23, with a peak HLOD of 1.84 (P=.004), and an estimate of the proportion of families linked (alpha) of 0.14, at D8S1130. In the 79 families with average age at diagnosis >65 years, an allele-sharing LOD score of 2.64 (P=.0005) was observed, and six markers spanning a distance of 10 cM had LOD scores >2.0. Interestingly, the small number of Ashkenazi Jewish pedigrees (n=11) analyzed in this study contributed disproportionately to this linkage. Mutation screening in HPC probands and association analyses in case subjects (a group that includes HPC probands and unrelated case subjects) and unaffected control subjects were carried out for the putative prostate cancer-susceptibility gene, PG1, previously localized to the 8p22-23 region. No statistical differences in the allele, genotype, or haplotype frequencies of the SNPs or other sequence variants in the PG1 gene were observed between case and control subjects. However, case subjects demonstrated a trend toward higher homozygous rates of less-frequent alleles in all three PG1 SNPs, and overtransmission of a PG1 variant to case subjects was observed. In summary, these results provide evidence for the existence of a prostate cancer-susceptibility gene at 8p22-23. Evaluation of the PG1 gene and other candidate genes in this area appears warranted.


Subject(s)
Chromosome Mapping , Chromosomes, Human, Pair 8/genetics , Genetic Linkage/genetics , Genetic Predisposition to Disease/genetics , Prostatic Neoplasms/genetics , Age of Onset , Alleles , DNA Mutational Analysis , Female , Gene Frequency/genetics , Genetic Markers/genetics , Genetic Testing , Genotype , Humans , Jews/genetics , Lod Score , Male , Microsatellite Repeats/genetics , Molecular Sequence Data , Mutation/genetics , Odds Ratio , Pedigree , Polymorphism, Single Nucleotide/genetics , Polymorphism, Single-Stranded Conformational , Prostatic Neoplasms/epidemiology , Racial Groups/genetics
14.
J Biol Chem ; 276(37): 34862-70, 2001 Sep 14.
Article in English | MEDLINE | ID: mdl-11461915

ABSTRACT

Flagellins from three strains of Campylobacter jejuni and one strain of Campylobacter coli were shown to be extensively modified by glycosyl residues, imparting an approximate 6000-Da shift from the molecular mass of the protein predicted from the DNA sequence. Tryptic peptides from C. jejuni 81-176 flagellin were subjected to capillary liquid chromatography-electrospray mass spectrometry with a high/low orifice stepping to identify peptide segments of aberrant masses together with their corresponding glycosyl appendages. These modified peptides were further characterized by tandem mass spectrometry and preparative high performance liquid chromatography followed by nano-NMR spectroscopy to identify the nature and precise site of glycosylation. These analyses have shown that there are 19 modified Ser/Thr residues in C. jejuni 81-176 flagellin. The predominant modification found on C. jejuni flagellin was O-linked 5,7-diacetamido-3,5,7,9-tetradeoxy-l-glycero-l-manno-nonulosonic acid (pseudaminic acid, Pse5Ac7Ac) with additional heterogeneity conferred by substitution of the acetamido groups with acetamidino and hydroxyproprionyl groups. In C. jejuni 81-176, the gene Cj1316c, encoding a protein of unknown function, was shown to be involved in the biosynthesis and/or the addition of the acetamidino group on Pse5Ac7Ac. Glycosylation is not random, since 19 of the total 107 Ser/Thr residues are modified, and all but one of these are restricted to the central, surface-exposed domain of flagellin when folded in the filament. The mechanism of attachment appears unrelated to a consensus peptide sequence but is rather based on surface accessibility of Ser/Thr residues in the folded protein.


Subject(s)
Campylobacter jejuni/chemistry , Flagellin/chemistry , Glycopeptides/analysis , Amino Acid Sequence , Glycosylation , Mass Spectrometry , Molecular Sequence Data
15.
Cancer Res ; 61(12): 4683-8, 2001 Jun 15.
Article in English | MEDLINE | ID: mdl-11406537

ABSTRACT

Critical aspects of the biology and molecular basis for prostate malignancy remain poorly understood. To reveal fundamental differences between benign and malignant growth of prostate cells, we performed gene expression profiling of primary human prostate cancer and benign prostatic hyperplasia (BPH) using cDNA microarrays consisting of 6500 human genes. Frozen prostate specimens were processed to facilitate extraction of RNA from regions of tissue enriched in either benign or malignant epithelial cell growth within a given specimen. Gene expression in each of the 16 prostate cancer and nine BPH specimens was compared with a common reference to generate normalized measures for each gene across all of the samples. Using an analysis of complete pairwise comparisons of expression profiles among all of the samples, we observed clearly discernable patterns of overall gene expression that differentiated prostate cancer from BPH. Further analysis of the data identified 210 genes with statistically significant differences in expression between prostate cancer and BPH. These genes include many not recognized previously as differentially expressed in prostate cancer and BPH, including hepsin, which codes for a transmembrane serine protease. This study reveals for the first time that significant and widespread differences in gene expression patterns exist between benign and malignant growth of the prostate gland. Gene expression analysis of prostate tissues should help to disclose the molecular mechanisms underlying prostate malignant growth and identify molecular markers for diagnostic, prognostic, and therapeutic use.


Subject(s)
Gene Expression Profiling , Gene Expression Regulation, Neoplastic , Humans , Male , Multigene Family , Prostatic Hyperplasia/genetics , Prostatic Hyperplasia/metabolism , Prostatic Hyperplasia/pathology , Prostatic Neoplasms/genetics , Prostatic Neoplasms/metabolism , Prostatic Neoplasms/pathology
16.
Hum Genet ; 108(4): 335-45, 2001 Apr.
Article in English | MEDLINE | ID: mdl-11379880

ABSTRACT

Three prostate cancer susceptibility genes have been reported to be linked to different regions on chromosome 1: HPC1 at 1q24-25, PCAP at 1q42-43, and CAPB at 1p36. Replication studies analyzing each of these regions have yielded inconsistent results. To evaluate linkage across this chromosome systematically, we performed multipoint linkage analyses with 50 microsatellite markers spanning chromosome 1 in 159 hereditary prostate cancer families (HPC), including 79 families analyzed in the original report describing HPC1 linkage. The highest lod scores for the complete dataset of 159 families were observed at 1q24-25 at which the parametric lod score assuming heterogeneity (hlod) was 2.54 (P=0.0006) with an allele sharing lod of 2.34 (P=0.001) at marker D1S413, although only weak evidence was observed in the 80 families not previously analyzed for this region (hlod=0.44, P=0.14, and allele sharing lod=0.67, P=0.08). In the complete data set, the evidence for linkage across this region was very broad, with allele sharing lod scores greater than 0.5 extending approximately 100 cM from 1p13 to 1q32, possibly indicating the presence of multiple susceptibility genes. Elsewhere on chromosome 1, some evidence of linkage was observed at 1q42-43, with a peak allele sharing lod of 0.56 (P=0.11) and hlod of 0.24 (P=0.25) at D1S235. For analysis of the CAPB locus at 1p36, we focused on six HPC families in our collection with a history of primary brain cancer; four of these families had positive linkage results at 1p36, with a peak allele sharing lod of 0.61 (P=0.09) and hlod of 0.39 (P=0.16) at D1S407 in all six families. These results are consistent with the heterogeneous nature of hereditary prostate cancer, and the existence of multiple loci on chromosome 1 for this disease.


Subject(s)
Chromosomes, Human, Pair 1 , Genetic Linkage , Prostatic Neoplasms/genetics , Chromosome Mapping , Genetic Diseases, Inborn/genetics , Genetic Predisposition to Disease/genetics , Humans , Male , Microsatellite Repeats
17.
J Midwifery Womens Health ; 46(1): 17-23, 2001.
Article in English | MEDLINE | ID: mdl-11300302

ABSTRACT

OBJECTIVE: In 1998, the screening and treatment practices of certified nurse-midwives (CNMs) for group B streptococcal (GBS) infection during pregnancy were studied and evaluated for their consistency with the 1996 perinatal GBS prevention guidelines of the Centers for Disease Control and Prevention (CDC). METHODOLOGY: Five hundred thirty-nine surveys were completed by CNMs attending the 1998 American College of Nurse-Midwives' Convention. Of these, 502 (94.7%) reported a practice policy for GBS prophylaxis. RESULTS: The Culture-Based Approach was used by 66.7% and the Obstetrical Risk Factor Approach by 28%. Most (69%) reported using multiple culture sites, most commonly the proximal vagina and anorectal area (33.2%), followed by the distal vagina and anorectal area (26.7%), and the anorectal area and proximal and distal vagina (7.1%). Most CNMs (92.5%) reported treating GBS intrapartally, with penicillin the most frequently reported antimicrobial (55.0%) used, and most (94.2%) reporting treatment through labor until birth. CONCLUSION: Overall, GBS prophylaxis practices among survey respondents comply with 1996 CDC recommendations; however, GBS screening practices show room for improvement and the need for continuing education that emphasizes the CDC guidelines, updates as they become available, and other new literature about the topic. In addition, heightened awareness among all perinatal providers is needed with respect to CDC guidelines, especially as they pertain to variations in culture sites, identification of risk categories, and the selection of appropriate antimicrobial treatment agents.


Subject(s)
Guideline Adherence/standards , Nurse Midwives/standards , Pregnancy Complications, Infectious/diagnosis , Prenatal Care/standards , Streptococcal Infections/diagnosis , Streptococcus agalactiae , Centers for Disease Control and Prevention, U.S. , Data Collection , Female , Humans , Mass Screening/standards , Practice Guidelines as Topic , Pregnancy , Pregnancy Complications, Infectious/drug therapy , Pregnancy Complications, Infectious/prevention & control , Risk Factors , Streptococcal Infections/drug therapy , Streptococcal Infections/prevention & control , United States
18.
Am J Hum Genet ; 68(4): 901-11, 2001 Apr.
Article in English | MEDLINE | ID: mdl-11254448

ABSTRACT

To investigate the relationship between HPC2/ELAC2 and prostate cancer risk, we performed the following analyses: (1) a linkage study of six markers in and around the HPC2/ELAC2 gene at 17p11 in 159 pedigrees with hereditary prostate cancer (HPC); (2) a mutation-screening analysis of all coding exons of the gene in 93 probands with HPC; (3) family-based and population-based association study of common HPC2/ELAC2 missense variants in 159 probands with HPC, 249 patients with sporadic prostate cancer, and 222 unaffected male control subjects. No evidence for linkage was found in the total sample, nor in any subset of pedigrees based on characteristics that included age at onset, number of affected members, male-to-male disease transmission, or race. Furthermore, only the two previously reported missense changes (Ser217Leu and Ala541Thr) were identified by mutational analysis of all HPC2/ELAC exons in 93 probands with HPC. In association analyses, family-based tests did not reveal excess transmission of the Leu217 and/or Thr541 alleles to affected offspring, and population-based tests failed to reveal any statistically significant difference in the allele frequencies of the two polymorphisms between patients with prostate cancer and control subjects. The results of this study lead us to reject the three alternative hypotheses of (1) a highly penetrant, major prostate cancer-susceptibility gene at 17p11, (2) the allelic variants Leu217 or Thr541 of HPC2/ELAC2 as high-penetrance mutations, and (3) the variants Leu217 or Thr541 as low-penetrance, risk-modifying alleles. However, we did observe a trend of higher Leu217 homozygous carrier rates in patients than in control subjects. Considering the impact of genetic heterogeneity, phenocopies, and incomplete penetrance on the linkage and association studies of prostate cancer and on the power to detect linkage and association in our study sample, our results cannot rule out the possibility of a highly penetrant prostate cancer gene at this locus that only segregates in a small number of pedigrees. Nor can we rule out a prostate cancer-modifier gene that confers a lower-than-reported risk. Additional larger studies are needed to more fully evaluate the role of this gene in prostate cancer risk.


Subject(s)
Genetic Linkage/genetics , Genetic Predisposition to Disease/genetics , Neoplasm Proteins/genetics , Prostatic Neoplasms/genetics , Age of Onset , Alleles , Amino Acid Substitution/genetics , Chromosomes, Human, Pair 17/genetics , DNA Mutational Analysis , Exons/genetics , Gene Frequency/genetics , Genetic Testing , Genotype , Humans , Lod Score , Male , Microsatellite Repeats/genetics , Mutation/genetics , Pedigree , Penetrance , Polymorphism, Single Nucleotide/genetics , Prostatic Neoplasms/epidemiology , White People/genetics
20.
Prostate ; 45(4): 323-34, 2000 Dec 01.
Article in English | MEDLINE | ID: mdl-11102958

ABSTRACT

BACKGROUND: E-cadherin and alpha-catenin are components of adherens junctions which mediate calcium-dependent, cell-cell adhesion in a homotypic manner. Both these molecules have been defined as useful tumor markers as their altered expression correlates with increased tumor aggressiveness and dedifferentiation. More recently, alterations of a third component of adherens junctions, beta-catenin, have been observed to play a role in several human cancers. Dysregulation of beta-catenin, either by direct mutation or by defects in interacting pathways/regulators, can result in its cytoplasmic accumulation and nuclear translocation. In the nucleus, beta-catenin forms a transcriptional complex capable of upregulating target genes, many of which encode proliferative factors. Given its oncogenic activity and connection to human cancer, we examined the beta-catenin gene and its expression in prostate cancer. METHODS: By single-stranded conformational polymorphism (SSCP) and DNA sequencing analyses, we screened exon 3 of beta-catenin from a panel of 81 primary tumors obtained at radical prostatectomy, 22 lymph node metastases from untreated patients, and a unique set of 61 metastatic tissues from 19 patients who died of hormone-refractory disease. RESULTS: We found putative activating mutations (missense and deletion) at a rate of 5% (7/138). One patient had the same 72 base pair deletion in each of nine separate metastases examined, indicating that this change was associated with a clonal population of metastatic cells. CONCLUSIONS: Immunohistological staining of mutation-positive tumors demonstrated beta-catenin accumulation and nuclear localization in a heterogeneous fashion. Consistent with this in vivo finding, our in vitro analyses demonstrate that certain mutations can result in increased beta-catenin nuclear activity in prostate cancer cell lines. These data implicate the beta-catenin signaling pathway in the development of a subset of prostate cancers.


Subject(s)
Cytoskeletal Proteins/genetics , Mutation, Missense , Prostatic Neoplasms/genetics , Sequence Deletion , Trans-Activators , Animals , Cytoskeletal Proteins/biosynthesis , DNA Mutational Analysis , DNA, Neoplasm/genetics , Exons , Humans , Immunohistochemistry , Male , Microscopy, Fluorescence , Neoplasm Metastasis , Neoplasm Staging , Polymorphism, Single-Stranded Conformational , Prostatic Neoplasms/metabolism , Prostatic Neoplasms/pathology , Transplantation, Heterologous , Tumor Cells, Cultured , beta Catenin
SELECTION OF CITATIONS
SEARCH DETAIL
...